Fentanyl Injectable Solution Recalled for Unvalidated Sterilization Cycles
Central Admixture Pharmacy Services is recalling 848 bags of fentanyl injection nationwide due to lack of validated sterilization processes that assure product sterility. Multiple lots distributed to healthcare facilities are affected.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: FDA Class II classification with a risk-of-harm product (injectable pharmaceutical) due to unvalidated sterilization processes creating potential contamination risk. No illnesses, injuries, or deaths are reported in the source, so per the rubric this meets the criteria for High (3) rather than Severe (4).
Plain-English summary
Central Admixture Pharmacy Services, Inc. is recalling 848 bags of fentanyl injection (2500 mcg/50 mL, 50 mcg/mL, in 100 mL bags). The product was distributed nationwide.
The recall was initiated because validation data for sanitization cycles was not available, meaning the company cannot assure that the sterilization process was effective. This creates a potential risk that the distributed product may not be sterile and could be contaminated.
Affected lots include: 17-270533 (Exp. 7/16/2023), 17-270580 and 17-270581 (Exp. 7/17/2023), 17-270654 (Exp. 7/18/2023), 17-271044 (Exp. 7/24/2023), 17-271243 (Exp. 7/26/2023), 17-271439 (Exp. 7/30/2023), and 17-271562 (Exp. 8/1/2023). Healthcare facilities and pharmacies that received these lots should verify their inventory.
If your facility has received this product, do not use it. Contact Central Admixture Pharmacy Services, Inc. at 7935 Dunbrook Road, Suite C, San Diego, CA 92126, or notify the FDA for return instructions.
The recalled product
- Product
- fentaNYL, 2500 mcg/50 mL, (50 mcg/mL), 100 mL bag, Central Admixture Pharmacy Services, Inc., 7935 Dunbrook Road, Suite C, San Diego, CA 92126, NDC: 71286-2003-4
- Manufacturer
- Central Admixture Pharmacy Services Inc
- Category
- Drug — Compounded Injectable
- Hazard
- sterility-failure
- contamination-risk
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (15)
- Lot: 17-270533
- Exp. 7/16/2023
- 17-270580
- 17-270581
- Exp. 7/17/2023
- 17-270654
- Exp. 7/18/2023
- 17-271044
- Exp. 7/24/2023
- 17-271243
- Exp. 7/26/2023
- 17-271439
- Exp. 7/30/2023
- 17-271562
- Exp. 8/1/2023.
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27